Dong Luo

1.5k total citations
51 papers, 1.1k citations indexed

About

Dong Luo is a scholar working on Pulmonary and Respiratory Medicine, Biomedical Engineering and Molecular Biology. According to data from OpenAlex, Dong Luo has authored 51 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 13 papers in Biomedical Engineering and 12 papers in Molecular Biology. Recurrent topics in Dong Luo's work include Nanoplatforms for cancer theranostics (12 papers), Nanoparticle-Based Drug Delivery (5 papers) and Photodynamic Therapy Research Studies (5 papers). Dong Luo is often cited by papers focused on Nanoplatforms for cancer theranostics (12 papers), Nanoparticle-Based Drug Delivery (5 papers) and Photodynamic Therapy Research Studies (5 papers). Dong Luo collaborates with scholars based in China, United States and United Kingdom. Dong Luo's co-authors include Xinning Wang, James P. Basilion, Clemens Burda, Gleb B. Sukhorukov, Gopalakrishnan Ramamurthy, James P. Basilion, David Gould, Michael J. Cattell, Saroash Shahid and Robin N. Poston and has published in prestigious journals such as Journal of the American Chemical Society, SHILAP Revista de lepidopterología and Nano Letters.

In The Last Decade

Dong Luo

48 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dong Luo China	22	501	307	293	281	219	51	1.1k
Yanchun Wei China	18	740 1.5×	356 1.2×	526 1.8×	241 0.9×	305 1.4×	51	1.3k
Zuhong Li China	18	696 1.4×	433 1.4×	370 1.3×	165 0.6×	311 1.4×	44	1.3k
Smriti Singh Germany	23	587 1.2×	523 1.7×	235 0.8×	115 0.4×	469 2.1×	79	1.6k
Hongshan Zhong China	18	673 1.3×	293 1.0×	419 1.4×	207 0.7×	333 1.5×	53	1.5k
Zhengjie Zhou China	17	713 1.4×	356 1.2×	252 0.9×	88 0.3×	374 1.7×	33	1.2k
Kim M. Tsoi Canada	11	971 1.9×	520 1.7×	691 2.4×	143 0.5×	524 2.4×	36	2.0k
Francesca Pagliari Italy	18	490 1.0×	366 1.2×	489 1.7×	155 0.6×	387 1.8×	40	1.7k
Jingsong Lu China	19	498 1.0×	225 0.7×	276 0.9×	74 0.3×	182 0.8×	61	1.2k
Xiao Cheng China	20	536 1.1×	328 1.1×	261 0.9×	166 0.6×	644 2.9×	41	1.7k

Countries citing papers authored by Dong Luo

Since Specialization

Citations

This map shows the geographic impact of Dong Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dong Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dong Luo more than expected).

Fields of papers citing papers by Dong Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dong Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dong Luo. The network helps show where Dong Luo may publish in the future.

Co-authorship network of co-authors of Dong Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Dong Luo. A scholar is included among the top collaborators of Dong Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dong Luo. Dong Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luo, Dong, Jie Hu, Xueyi Li, et al.. (2025). Selective recognition of bacterial phospholipids by antimicrobial peptides: Employing a host-guest-mediated competitive inhibition strategy. Biomaterials. 322. 123392–123392. 3 indexed citations

Jiang, Min, Xin Zhang, Rongkun Zheng, et al.. (2025). Harnessing prazosin for tumors: Liposome hybrid nanovesicles activate tumor immunotherapy via autophagy inhibition. Biomaterials. 319. 123184–123184. 2 indexed citations

Liu, Shangxin, Tianyu Wu, Dong Luo, et al.. (2025). Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma. Cell Reports Medicine. 6(7). 102200–102200.

Li, Xueyi, Liping Zhao, Songyin Huang, et al.. (2025). Hydrophobicity-to-cationic amphipathicity transformable antimicrobial polypeptides for the prevention of medical implant-associated infections. Biomaterials. 325. 123564–123564. 1 indexed citations

Mwizerwa, Jean Pierre, Haotian Wu, Lijun Xu, et al.. (2024). Surface modification of LiFePO4 cathode enabled by highly Li+ mobility wrapping layer towards high energy and power density. Applied Materials Today. 40. 102423–102423. 2 indexed citations

Luo, Dong, et al.. (2024). Role of Myeloid Cells in Regulating New Mechanisms of Bone Aging and Drug Therapy. Journal of Biosciences and Medicines. 12(11). 30–43.

Luo, Dong, Xinning Wang, Gopalakrishnan Ramamurthy, et al.. (2023). Evaluation of a photodynamic therapy agent using a canine prostate cancer model. The Prostate. 83(12). 1176–1185. 4 indexed citations

Chen, Tao, Bingjie Zheng, Z. Zhang, et al.. (2023). The Incidence and Prognosis Value of Perineural Invasion in Rectal Carcinoma: From Meta-Analyses and Real-World Clinical Pathological Features. Clinical Oncology. 35(10). e611–e621. 11 indexed citations

Luo, Dong, Dongqiang Liu, Shanshan Shi, et al.. (2022). Raised SPINK1 levels play a role in angiogenesis and the transendothelial migration of ALL cells. Scientific Reports. 12(1). 2999–2999. 3 indexed citations

10.

Wang, Xinning, et al.. (2022). A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer. Theranostics. 12(5). 2335–2350. 13 indexed citations

11.

Li, Hao, Dong Luo, Xinning Wang, et al.. (2021). Magnetic Resonance Imaging of PSMA-Positive Prostate Cancer by a Targeted and Activatable Gd(III) MR Contrast Agent. Journal of the American Chemical Society. 143(41). 17097–17108. 48 indexed citations

12.

Zhu, Hongwei, Wenzhe Gao, Xia Li, et al.. (2021). S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Pancreatology. 21(3). 589–598. 20 indexed citations

13.

Luo, Dong, et al.. (2018). Controlled release of chlorhexidine from a HEMA-UDMA resin using a magnetic field. Dental Materials. 34(5). 764–775. 12 indexed citations

14.

Luo, Dong, Robin N. Poston, David Gould, & Gleb B. Sukhorukov. (2018). Magnetically targetable microcapsules display subtle changes in permeability and drug release in response to a biologically compatible low frequency alternating magnetic field. Materials Science and Engineering C. 94. 647–655. 34 indexed citations

15.

Li, Shuying, et al.. (2016). Different interventions in preventing opioid-induced cough: a meta-analysis. Journal of Clinical Anesthesia. 34. 440–447. 30 indexed citations

16.

Ni, Juan, et al.. (2015). Effect of Dexmedetomidine on Preventing Postoperative Agitation in Children: A Meta-Analysis. PLoS ONE. 10(5). e0128450–e0128450. 33 indexed citations

17.

Shen, Ying‐Chun, Yingchao Zhao, Hongfeng Gou, et al.. (2015). Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial. European Journal of Surgical Oncology. 41(8). 1082–1088. 16 indexed citations

18.

Luo, Dong & Rong Zhou. (2014). Research Progress of Heparanase and Related Diseases. 10(4). 538–541.

19.

Wang, Shui, Yuanyuan Tian, Dongze Wu, et al.. (2012). Genetic variation of CTNNB1 gene is associated with susceptibility and prognosis of gastric cancer in a Chinese population. Mutagenesis. 27(6). 623–630. 30 indexed citations

20.

Foster, Graham R., Stefan Zeuzem, Pietro Andreoné, et al.. (2011). OP03 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results: Abstract OP03 Table 1. Gut. 60(Suppl 2). A50.3–A51. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact